Tianxiao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tianxiao Li has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Yingkun He
Cerebrovascular and Neurosurgery Department of Stroke Center, Henan Provincial People’s Hospital (Zhengzhou University People’s Hospital), Zhengzhou, China
12 shared publications Yanyan He
Cerebrovascular and Neurosurgery Department of Stroke Center, Henan Provincial People’s Hospital (Zhengzhou University People’s Hospital), Zhengzhou, China
11 shared publicationsLin Duan
Henan Provincial People’s Hospital, Department of Cerebrovascular Disease and Neurosurgery, Zhengzhou University People’s Hospital
8 shared publicationsChi Ma
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
6 shared publicationsDehua Guo
Department of Cerebrovascular Disease and Neurosurgery, Zhengzhou University People's Hospital, Henan University People's Hospital, Henan Provincial People's Hospital, Henan Provincial Neurointerventional Engineering Research Center, Henan International Joint Laboratory of Cerebrovascular Disease and Henan Engineering Research Center of Cerebrovascular Intervention, Zhengzhou, 450003, China
6 shared publicationsRufeng Jia
Department of Cerebrovascular Disease, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, China
6 shared publications
Latest Publications
- 25 September 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (5) , 106
Exogenous Hydrogen Sulfide Donors Suppress Neointimal Hyperplasia by Modulating Mitochondrial Dysfunction in Vascular Smooth Muscle Cells
- 25 September 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (5) , 106
Exogenous Hydrogen Sulfide Donors Suppress Neointimal Hyperplasia by Modulating Mitochondrial Dysfunction in Vascular Smooth Muscle Cells
- Open Access
- 31 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1721125
NAMPT inhibition induces ferroptosis via mitochondrial metabolic reprogramming to enhance tumour immunogenicity in glioblastoma
Background: Ferroptosis has recently been recognised as an immunogenic form of regulated cell death. Nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in the NAD + salvage pathway, is highly expressed in glioblastoma and represents a promising metabolic target. Methods: We investigated the effects of the NAMPT inhibitor GMX1778 on ferroptosis and tumour immunogenicity in glioblastoma cells. Mitochondrial NAD + levels, SIRT3 activity, and ferroptosis-related markers were analysed by biochemical assays and western blotting. The PERK–CHOP pathway and markers of enhanced immunogenicity (calreticulin exposure, ATP release, HMGB1 release) were evaluated. The role of ferroptosis was verified using inducers and inhibitors. Macrophage polarisation was assessed in co-culture with treated tumour cells. In vivo immune responses were examined using a prophylactic vaccination model in GL261 glioma-bearing mice. Results: NAMPT inhibition by GMX1778 depleted mitochondrial NAD + , suppressed SIRT3, and induced ROS accumulation with downregulation of GPX4, leading to ferroptosis. This was accompanied by strong activation of ER stress and increased markers of immunogenicity. Ferroptosis inducers amplified, while inhibitors suppressed, these responses. GMX1778-treated glioma cells promoted macrophage polarisation from an M2 to M1 phenotype. In vivo , GMX1778 pre-treatment significantly reduced intracranial tumour incidence and enhanced anti-tumour immune responses in mice. Conclusion: NAMPT inhibition induces ferroptosis via mitochondrial metabolic reprogramming and subsequently enhances tumour immunogenicity through ER stress activation. These findings highlight a novel metabolic–immune mechanism and suggest that NAMPT inhibitors could serve as promising agents for glioblastoma therapy.
- 31 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1721125
Open AccessNAMPT inhibition induces ferroptosis via mitochondrial metabolic reprogramming to enhance tumour immunogenicity in glioblastoma
Background: Ferroptosis has recently been recognised as an immunogenic form of regulated cell death. Nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in the NAD + salvage pathway, is highly expressed in glioblastoma and represents a promising metabolic target. Methods: We investigated the effects of the NAMPT inhibitor GMX1778 on ferroptosis and tumour immunogenicity in glioblastoma cells. Mitochondrial NAD + levels, SIRT3 activity, and ferroptosis-related markers were analysed by biochemical assays and western blotting. The PERK–CHOP pathway and markers of enhanced immunogenicity (calreticulin exposure, ATP release, HMGB1 release) were evaluated. The role of ferroptosis was verified using inducers and inhibitors. Macrophage polarisation was assessed in co-culture with treated tumour cells. In vivo immune responses were examined using a prophylactic vaccination model in GL261 glioma-bearing mice. Results: NAMPT inhibition by GMX1778 depleted mitochondrial NAD + , suppressed SIRT3, and induced ROS accumulation with downregulation of GPX4, leading to ferroptosis. This was accompanied by strong activation of ER stress and increased markers of immunogenicity. Ferroptosis inducers amplified, while inhibitors suppressed, these responses. GMX1778-treated glioma cells promoted macrophage polarisation from an M2 to M1 phenotype. In vivo , GMX1778 pre-treatment significantly reduced intracranial tumour incidence and enhanced anti-tumour immune responses in mice. Conclusion: NAMPT inhibition induces ferroptosis via mitochondrial metabolic reprogramming and subsequently enhances tumour immunogenicity through ER stress activation. These findings highlight a novel metabolic–immune mechanism and suggest that NAMPT inhibitors could serve as promising agents for glioblastoma therapy.
- 27 September 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (8) , 1824-1830
Development of a rabbit model of eccentric carotid atherosclerotic stenosis via localized cryoinjury
Background The eccentric stenosis morphology in patients with intracranial atherosclerotic stenosis (ICAS) has a critical impact on the efficacy of endovascular treatment. This study aimed to establish a rabbit model of eccentric carotid atherosclerotic stenosis that mimics the pathophysiological and morphological characteristics of eccentric plaques in humans. Methods Rabbits received localized cryoinjury of the right carotid artery after 2 weeks of a high fat, high cholesterol diet, followed by an additional 8 weeks on the same diet. On the experimental endpoint, comprehensive analyses of the model’s pathological changes were conducted using serum lipid analysis, DSA, optical coherence tomography (OCT), histopathological analysis, and immunohistochemistry. Results The high fat, high cholesterol diet significantly elevated serum lipid levels in rabbits. Hematoxylin and eosin staining results at 24 hours postoperatively revealed focal intimal damage induced by 5 s of cryoinjury. After localized cryoinjury and high fat, high cholesterol diet feeding, DSA results demonstrated significant carotid stenosis, with a stenosis degree of 47±5% and a length of approximately 9 mm. OCT images revealed eccentric fibrous plaque formation at the stenotic site. Morphological analysis of the plaque samples demonstrated a plaque eccentricity index of 0.66±0.05 and a plaque burden of 60.68±7.41%. Histopathological analysis showed that atherosclerotic lesions developed in all rabbits of the model group. Among them, three rabbits had intermediate lesions, one rabbit had atheroma, and eight rabbits had fibroatheroma. Conclusions This study successfully established a rabbit model of eccentric carotid atherosclerotic stenosis, providing a novel experimental platform for transformation research of neurointerventional devices.
- 27 September 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (8) , 1824-1830
Development of a rabbit model of eccentric carotid atherosclerotic stenosis via localized cryoinjury
Background The eccentric stenosis morphology in patients with intracranial atherosclerotic stenosis (ICAS) has a critical impact on the efficacy of endovascular treatment. This study aimed to establish a rabbit model of eccentric carotid atherosclerotic stenosis that mimics the pathophysiological and morphological characteristics of eccentric plaques in humans. Methods Rabbits received localized cryoinjury of the right carotid artery after 2 weeks of a high fat, high cholesterol diet, followed by an additional 8 weeks on the same diet. On the experimental endpoint, comprehensive analyses of the model’s pathological changes were conducted using serum lipid analysis, DSA, optical coherence tomography (OCT), histopathological analysis, and immunohistochemistry. Results The high fat, high cholesterol diet significantly elevated serum lipid levels in rabbits. Hematoxylin and eosin staining results at 24 hours postoperatively revealed focal intimal damage induced by 5 s of cryoinjury. After localized cryoinjury and high fat, high cholesterol diet feeding, DSA results demonstrated significant carotid stenosis, with a stenosis degree of 47±5% and a length of approximately 9 mm. OCT images revealed eccentric fibrous plaque formation at the stenotic site. Morphological analysis of the plaque samples demonstrated a plaque eccentricity index of 0.66±0.05 and a plaque burden of 60.68±7.41%. Histopathological analysis showed that atherosclerotic lesions developed in all rabbits of the model group. Among them, three rabbits had intermediate lesions, one rabbit had atheroma, and eight rabbits had fibroatheroma. Conclusions This study successfully established a rabbit model of eccentric carotid atherosclerotic stenosis, providing a novel experimental platform for transformation research of neurointerventional devices.
- Open Access
Evaluation of safety and efficacy of intracranial self-expanding drug-eluting stents for symptomatic intracranial atherosclerotic stenosis: a prospective, multicentre, randomised controlled, superiority clinical trial protocol
Background In-stent restenosis (ISR) is a crucial factor that affects the long-term efficacy of intracranial bare metal stent (BMS) implantation for intracranial atherosclerotic stenosis (ICAS). Patients with intracranial ISR are at a high risk of recurrent ischaemic events. The NOVA intracranial drug-eluting stent (DES) trial demonstrates that a DES can reduce ISR and stroke recurrence after intracranial bare stent implantation. However, the application of balloon-expanded DES necessitates specific vascular conditions. The objective of this study is to assess the safety and efficacy of self-expanding DES for treating symptomatic ICAS (sICAS). Methods This is a prospective, multicentre, randomised, controlled, superiority clinical trial that is conducted in 16 clinical trial centres in China. This study aims to recruit 208 patients with sICAS. Eligible subjects are randomly assigned to two groups at a ratio of 1:1. The experimental group is treated with DES (Xinwei intracranial DES system). The control group is treated with BMS (Wingspan intracranial stent system). All subjects are followed up within 7 days after surgery or before discharge; 30 days after surgery; and 6, 12 and 24 months after surgery. The primary outcome of the trial is the incidence of ISR at 6 months after surgery to verify the safety and efficacy of intracranial DESs. After 6 months of follow-up, the clinical summary report is issued for product registration application, and the follow-up of 12 months and 24 months after operation is conducted to evaluate the medium and long-term efficacy. Ethics and dissemination The study involving human participants is reviewed and approved by the Ethics Committee of Drugs (devices) Clinical Experiment in Henan Provincial People’s Hospital (reference number: AF/SC-08/05.0) and other research centres participating in the clinical trial (supplemental file 2). The results yield from this study will be presented at international conferences and sent to a peer-reviewed journal to be considered for publication. Trial registration number Registered on 2 November 2023 with Chinese clinical trial registry. Registration number is ChiCTR2300077271.
Open AccessEvaluation of safety and efficacy of intracranial self-expanding drug-eluting stents for symptomatic intracranial atherosclerotic stenosis: a prospective, multicentre, randomised controlled, superiority clinical trial protocol
Background In-stent restenosis (ISR) is a crucial factor that affects the long-term efficacy of intracranial bare metal stent (BMS) implantation for intracranial atherosclerotic stenosis (ICAS). Patients with intracranial ISR are at a high risk of recurrent ischaemic events. The NOVA intracranial drug-eluting stent (DES) trial demonstrates that a DES can reduce ISR and stroke recurrence after intracranial bare stent implantation. However, the application of balloon-expanded DES necessitates specific vascular conditions. The objective of this study is to assess the safety and efficacy of self-expanding DES for treating symptomatic ICAS (sICAS). Methods This is a prospective, multicentre, randomised, controlled, superiority clinical trial that is conducted in 16 clinical trial centres in China. This study aims to recruit 208 patients with sICAS. Eligible subjects are randomly assigned to two groups at a ratio of 1:1. The experimental group is treated with DES (Xinwei intracranial DES system). The control group is treated with BMS (Wingspan intracranial stent system). All subjects are followed up within 7 days after surgery or before discharge; 30 days after surgery; and 6, 12 and 24 months after surgery. The primary outcome of the trial is the incidence of ISR at 6 months after surgery to verify the safety and efficacy of intracranial DESs. After 6 months of follow-up, the clinical summary report is issued for product registration application, and the follow-up of 12 months and 24 months after operation is conducted to evaluate the medium and long-term efficacy. Ethics and dissemination The study involving human participants is reviewed and approved by the Ethics Committee of Drugs (devices) Clinical Experiment in Henan Provincial People’s Hospital (reference number: AF/SC-08/05.0) and other research centres participating in the clinical trial (supplemental file 2). The results yield from this study will be presented at international conferences and sent to a peer-reviewed journal to be considered for publication. Trial registration number Registered on 2 November 2023 with Chinese clinical trial registry. Registration number is ChiCTR2300077271.
- Open Access
- 18 November 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (2) , 255-266
Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase‐mutant lower‐grade gliomas
Objective: To differentiate glioma grading and determine isocitrate dehydrogenase (IDH) mutation status, which are crucial for prognosis assessment and treatment planning in glioma patients.Methods: This retrospective study included patients diagnosed with adult diffuse glioma from 1 January, 2018 to 31 July, 2023 in two independent institutions. It documented and analysed clinical and radiographic features. A nomogram model was constructed using stepwise regression to predict lower‐grade gliomas and IDH mutation status.Results: A total of 383 adult patients with diffuse glioma were included in the study, with Cohort A (297 patients) serving as the training set and Cohort B (86 patients) serving as the validation cohort. Consistent with previous reports, the Hyper fluid‐attenuated inversion recovery (FLAIR) rim sign exhibited higher sensitivity in lower‐grade gliomas for IDH mutant gliomas compared with the T2‐FLAIR mismatch sign. However, the Hyper FLAIR rim sign was also present in Grade 4 gliomas, and thus, the T2‐FLAIR mismatch sign exhibited better clinical efficacy in predicting glioma grade and IDH mutation compared with the Hyper FLAIR rim sign in clinical applications. Meanwhile, preoperative magnetic resonance spectroscopy (MRS) indicators, particularly the Cho/Cr ratio, have shown excellent performance in predicting glioma grade and IDH mutation status. The nomogram developed through stepwise regression demonstrated excellent predictive capabilities in distinguishing glioma grade and IDH mutation status.Interpretation: Combining imaging and molecular features, the predictive model established in this study offers a reliable non‐invasive tool for predicting glioma grading and IDH mutation status, aiding the clinical decision‐making process and improving patient management.
- 18 November 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (2) , 255-266
Open AccessComprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase‐mutant lower‐grade gliomas
Objective: To differentiate glioma grading and determine isocitrate dehydrogenase (IDH) mutation status, which are crucial for prognosis assessment and treatment planning in glioma patients.Methods: This retrospective study included patients diagnosed with adult diffuse glioma from 1 January, 2018 to 31 July, 2023 in two independent institutions. It documented and analysed clinical and radiographic features. A nomogram model was constructed using stepwise regression to predict lower‐grade gliomas and IDH mutation status.Results: A total of 383 adult patients with diffuse glioma were included in the study, with Cohort A (297 patients) serving as the training set and Cohort B (86 patients) serving as the validation cohort. Consistent with previous reports, the Hyper fluid‐attenuated inversion recovery (FLAIR) rim sign exhibited higher sensitivity in lower‐grade gliomas for IDH mutant gliomas compared with the T2‐FLAIR mismatch sign. However, the Hyper FLAIR rim sign was also present in Grade 4 gliomas, and thus, the T2‐FLAIR mismatch sign exhibited better clinical efficacy in predicting glioma grade and IDH mutation compared with the Hyper FLAIR rim sign in clinical applications. Meanwhile, preoperative magnetic resonance spectroscopy (MRS) indicators, particularly the Cho/Cr ratio, have shown excellent performance in predicting glioma grade and IDH mutation status. The nomogram developed through stepwise regression demonstrated excellent predictive capabilities in distinguishing glioma grade and IDH mutation status.Interpretation: Combining imaging and molecular features, the predictive model established in this study offers a reliable non‐invasive tool for predicting glioma grading and IDH mutation status, aiding the clinical decision‐making process and improving patient management.
- 14 August 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 141, 112896
Antitumor effects of IOX1 combined with bevacizumab-induced apoptosis and immunity on colorectal cancer cells
- 14 August 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 141, 112896
Antitumor effects of IOX1 combined with bevacizumab-induced apoptosis and immunity on colorectal cancer cells
- Open Access
- 1 November 2023
- Published by KEAI Publishing in Journal of Interventional Medicine
- Vol. 6 (4) , 180-186
A novel cerebrovascular drug-coated balloon catheter for treating symptomatic intracranial atherosclerotic stenosis lesions: Study protocol for a prospective, multicenter, single-arm, target-value clinical trial
Previous single-center studies have demonstrated that drug-coated balloons (DCBs) may reduce restenosis rates, which is an important factor affecting the prognosis for intracranial interventional therapy. However, currently available cardiac DCBs are not always suitable for the treatment of intracranial atherosclerotic stenosis (ICAS). This study aimed to evaluate the safety and efficacy of a novel DCB catheter designed for patients with severely symptomatic ICAS. This prospective, multicenter, single-arm, target-value clinical trial was conducted in 9 Chinese stroke centers to evaluate the safety and efficacy of a novel DCB catheter for treating symptomatic severe ICAS. Primary metrics and other indicators were collected and analyzed using SAS version 9.4 (SAS Institute, Cary, NC, USA). A total of 155 patients were enrolled in this study. The preliminary collection of follow-up data has been completed, while data quality control is ongoing. Results of this study demonstrated the patency rate, safety, and effectiveness of a novel on-label paclitaxel DCB designed for the treatment of ICAS. ChiCTR, ChiCTR2100047223. Registered June 11, 2021-Prospective registration, https://www.chictr.org.cn/ChiCTR2100047223.
- 1 November 2023
- Published by KEAI Publishing in Journal of Interventional Medicine
- Vol. 6 (4) , 180-186
Open AccessA novel cerebrovascular drug-coated balloon catheter for treating symptomatic intracranial atherosclerotic stenosis lesions: Study protocol for a prospective, multicenter, single-arm, target-value clinical trial
Previous single-center studies have demonstrated that drug-coated balloons (DCBs) may reduce restenosis rates, which is an important factor affecting the prognosis for intracranial interventional therapy. However, currently available cardiac DCBs are not always suitable for the treatment of intracranial atherosclerotic stenosis (ICAS). This study aimed to evaluate the safety and efficacy of a novel DCB catheter designed for patients with severely symptomatic ICAS. This prospective, multicenter, single-arm, target-value clinical trial was conducted in 9 Chinese stroke centers to evaluate the safety and efficacy of a novel DCB catheter for treating symptomatic severe ICAS. Primary metrics and other indicators were collected and analyzed using SAS version 9.4 (SAS Institute, Cary, NC, USA). A total of 155 patients were enrolled in this study. The preliminary collection of follow-up data has been completed, while data quality control is ongoing. Results of this study demonstrated the patency rate, safety, and effectiveness of a novel on-label paclitaxel DCB designed for the treatment of ICAS. ChiCTR, ChiCTR2100047223. Registered June 11, 2021-Prospective registration, https://www.chictr.org.cn/ChiCTR2100047223.
- Open Access
Dexmedetomidine decreases cerebral hyperperfusion incidence following carotid stenting: A randomized, double-blind trial
Background: Cerebral hyperperfusion syndrome (CHS) is not a common but severe complication after carotid artery stenting (CAS). We investigated whether prophylactic low-dose dexmedetomidine, a selective α 2 -adrenoceptor agonist, can decrease cerebral hyperperfusion induced brain injury after carotid artery stenting. Methods: This randomised, double-blind, placebo-controlled trial was conducted in a tertiary-care hospital in Zhengzhou, China. Patients aged 18 to 80 years old who had undergone CAS and from whom written informed consent was obtained, were enrolled between Jul 20, 2019 and Oct 10, 2022. Patients were randomly assigned to receive either intravenous dexmedetomidine (0·1 μg/kg/h, from insertion of the laryngeal mask until 72hr on postoperative day 3) (n = 80) or placebo (intravenous normal saline) (n = 80). The primary endpoint was the incidence of cerebral hyperperfusion (CH) and cerebral hyperperfusion syndrome (CHS), which were assessed six times with Transcranial Doppler sonography (TCD) during the postoperative three days. This study was registered with the Chinese Clinical Trial Registry, www.chictr.org.cn , ChiCTR1900024416. Results: CH occurred in 30 (37·5%) of 80 patients given a placebo and in 9 (11·2%) of 80 patients given dexmedetomidine (odds ratio [OR] 0·211, 95% CI 0·09-0·48; p<0·001). Further, CHS was significantly lower in the Dex group than in the placebo group (2.5% vs 13·75%; [OR] 0·16, 95% CI 0·03-0·71; p=0·017). Correspondingly, dexmedetomidine significantly upregulated serum brain-derived neurotrophic factor (BDNF) and downregulated neuronal injury biomarker neurofilament light chain (Nfl). The hierarchical clustering analysis revealed little difference in lipids metabolites between the two groups pre- and post-operatively, with Dex treatment uniquely increased lysphosphatidylethanolamine (LPE). Conclusions: A low prophylactic dose of dexmedetomidine significantly decreased the occurrence of cerebral hyperperfusion and cerebral hyperperfusion syndrome during the first three days after carotid artery stenting surgery.
Open AccessDexmedetomidine decreases cerebral hyperperfusion incidence following carotid stenting: A randomized, double-blind trial
Background: Cerebral hyperperfusion syndrome (CHS) is not a common but severe complication after carotid artery stenting (CAS). We investigated whether prophylactic low-dose dexmedetomidine, a selective α 2 -adrenoceptor agonist, can decrease cerebral hyperperfusion induced brain injury after carotid artery stenting. Methods: This randomised, double-blind, placebo-controlled trial was conducted in a tertiary-care hospital in Zhengzhou, China. Patients aged 18 to 80 years old who had undergone CAS and from whom written informed consent was obtained, were enrolled between Jul 20, 2019 and Oct 10, 2022. Patients were randomly assigned to receive either intravenous dexmedetomidine (0·1 μg/kg/h, from insertion of the laryngeal mask until 72hr on postoperative day 3) (n = 80) or placebo (intravenous normal saline) (n = 80). The primary endpoint was the incidence of cerebral hyperperfusion (CH) and cerebral hyperperfusion syndrome (CHS), which were assessed six times with Transcranial Doppler sonography (TCD) during the postoperative three days. This study was registered with the Chinese Clinical Trial Registry, www.chictr.org.cn , ChiCTR1900024416. Results: CH occurred in 30 (37·5%) of 80 patients given a placebo and in 9 (11·2%) of 80 patients given dexmedetomidine (odds ratio [OR] 0·211, 95% CI 0·09-0·48; p<0·001). Further, CHS was significantly lower in the Dex group than in the placebo group (2.5% vs 13·75%; [OR] 0·16, 95% CI 0·03-0·71; p=0·017). Correspondingly, dexmedetomidine significantly upregulated serum brain-derived neurotrophic factor (BDNF) and downregulated neuronal injury biomarker neurofilament light chain (Nfl). The hierarchical clustering analysis revealed little difference in lipids metabolites between the two groups pre- and post-operatively, with Dex treatment uniquely increased lysphosphatidylethanolamine (LPE). Conclusions: A low prophylactic dose of dexmedetomidine significantly decreased the occurrence of cerebral hyperperfusion and cerebral hyperperfusion syndrome during the first three days after carotid artery stenting surgery.